BR100 Increased By (0.01%)
BR30 Increased By (0.53%)
KSE100 Increased By (0.28%)
KSE30 Increased By (0.29%)
AGHA 6.35 Increased By ▲ 0.03 (0.47%)
BECO 4.39 Increased By ▲ 0.12 (2.81%)
BML 62.50 Increased By ▲ 0.05 (0.08%)
BOP 31.47 Increased By ▲ 0.24 (0.77%)
CNERGY 11.70 Increased By ▲ 0.11 (0.95%)
CSIL 5.92 Increased By ▲ 0.20 (3.5%)
FCCL 61.60 Increased By ▲ 0.06 (0.1%)
FFL 14.79 Decreased By ▼ -0.23 (-1.53%)
FNEL 1.23 No Change ▼ 0.00 (0%)
KEL 6.33 Increased By ▲ 0.07 (1.12%)
KOSM 5.90 Increased By ▲ 0.34 (6.12%)
LOTCHEM 24.79 Increased By ▲ 0.11 (0.45%)
MLCF 103.93 Decreased By ▼ -0.15 (-0.14%)
NBP 173.05 Decreased By ▼ -2.23 (-1.27%)
NCPL 51.85 Decreased By ▼ -0.92 (-1.74%)
NPL 54.19 Increased By ▲ 0.07 (0.13%)
OGDC 315.50 Increased By ▲ 2.11 (0.67%)
PACE 9.26 Increased By ▲ 0.06 (0.65%)
PAEL 35.51 Decreased By ▼ -0.29 (-0.81%)
PIBTL 13.65 Increased By ▲ 0.18 (1.34%)
PPL 226.60 Increased By ▲ 4.79 (2.16%)
PRL 80.30 Increased By ▲ 1.22 (1.54%)
PTC 46.89 Increased By ▲ 0.04 (0.09%)
SSGC 23.90 Increased By ▲ 0.03 (0.13%)
TBL 9.30 Decreased By ▼ -0.01 (-0.11%)
TELE 7.65 Increased By ▲ 0.26 (3.52%)
TPL 24.51 Decreased By ▼ -0.60 (-2.39%)
TPLP 13.04 Increased By ▲ 0.53 (4.24%)
TREET 26.05 Decreased By ▼ -0.20 (-0.76%)
TRG 53.38 Decreased By ▼ -0.06 (-0.11%)
World

Thailand on track to distribute locally made COVID-19 vaccines in June

  • Thailand's vaccine strategy revolves around production of AstraZeneca shots by local firm Siam Bioscience, owned by the Thai king's vast business holdings.
  • Siam Bioscience underwent a five-day virtual audit in December and all the batches it produces will also undergo quality testing.
Published Updated
By

BANGKOK: Thailand's plan to produce the AstraZeneca coronavirus vaccine locally is on track to be ready to begin mass inoculations in June, with a capacity to make up to 18 million doses per month, a senior official said on Friday.

It was still unclear how many would go to Thai citizens and how many would be exported to other Southeast Asian countries under a deal with AstraZeneca that has come under fire from opposition critics for being too slow and lacking transparency.

Thailand's vaccine strategy revolves around production of AstraZeneca shots by local firm Siam Bioscience, owned by the Thai king's vast business holdings.

Tests of the first batches are due to be completed by the end of May, the head of the National Vaccine Institute, Nakorn Premsri, told Reuters in an interview.

"The industrial batch will come out by June," Nakorn said.

Siam Bioscience underwent a five-day virtual audit in December and all the batches it produces will also undergo quality testing, AstraZeneca said in a statement.

Nakorn said Thailand chose to produce locally because it wanted to safeguard its own vaccine supply amid the global rush to protect against a virus that has killed more than two million people worldwide.

Thailand signed the AstraZeneca deal in October, putting it months behind nations such as the United Kingdom, the United States and India.

Thailand has ordered 61 million locally made doses from AstraZeneca - enough for 30.5 million people, or just over half the adult population, excluding people under 18 and pregnant women.

Until June, Thailand will rely on imported vaccines.

The first 50,000 imported doses from AstraZeneca are expected in February with 100,000 more due in the next few months, but on Friday Health Minister Anutin Charnvirakul warned that supply issues in Europe might cause delays.

Thailand has also ordered two million doses of China's Sinovac Biotech Ltd vaccines with 200,000 doses due in February, though it has yet to be approved by the regulator.

For most of last year Thailand was able to keep infections low, but a second wave broke out in December, bringing total cases to 17,023 and 76 deaths.

Comments

Comments are closed for this article.